Overview

The Effect of Darbepoetin Upon Rehabilitation for Colorectal Cancer Surgery

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
0
Participant gender:
All
Summary
The study is investigating whether randomization to perioperative darbepoetin alfa treatment improves the rehabilitation following surgery for colonic and rectal cancer.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Herning Hospital
Collaborator:
Amgen
Treatments:
Darbepoetin alfa
Criteria
Inclusion Criteria:

- Planned colonic and rectal surgery because of presumed cancer disease in the colon and
rectum

Exclusion Criteria:

- Psychiatric disease or dementia

- Diseases, that renders participation in the study impossible

- Thromboembolic disease within the last three months

- Dysregulated hypertension (systolic blood pressure>175 mmHg and/or diastolic blood
pressure>105 mmHg)

- Other diseases or causes that will contraindicate treatment with Darbepoetin Alfa

- Other diseases or causes that will contraindicate further treatment with Darbepoetin
Alfa

- Patients that preoperatively and/or four days postoperatively have a hemoglobin
concentration > 14 g/dl

- Former cancer disease

- Disseminated cancer disease

- Rectal cancer stage T4